The agreement, announced Monday, effectively buries the contentious July 31 special meeting that Murchinson had pushed to initiate a board coup. By securing three of the five board seats, the activist investor gains significant sway over the company's future trajectory. This resolution follows a aggressive campaign by Murchinson, which publicly accused the incumbent directors of poor oversight and questionable capital allocation.

Central to the conflict was a proposed transaction with Infinite Epigenetics, which Murchinson labeled a flawed deal that threatened to dilute shareholder value. The activist group argued that the board was mismanaging corporate resources, a claim that sparked the push for a total leadership overhaul. With the new directors now in place, the company pivots away from a prolonged proxy fight, leaving investors to watch how the reconstituted board handles the controversial acquisition strategy that triggered the dispute.